Cardiff Oncology, Inc. — Director's Dealing 2018

Jan 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Trovagene, Inc. (TROV)
CIK: 0001213037
Period of Report: 2018-01-02

Reporting Person: ADAMS THOMAS PHD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-02	Common Stock	M	16667	$0.00	Acquired	351959	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-02	Restricted Stock Units	$	M	16667	Disposed		Common Stock (16667)	Direct

Footnotes

F1: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017.

F2: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.

F3: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4.